Halozyme Therapeutics financials
$111.56−1.18%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $481.0M | $376.7M | $451.8M | $354.3M | $325.7M | $264.9M | $298.0M | $290.1M | $231.4M | $195.9M | $230.0M | $216.0M |
| Gross profit | $401.8M | $297.5M | $373.0M | $299.0M | $279.4M | $216.5M | $256.0M | $240.7M | $191.7M | $167.6M | $177.7M | $161.2M |
| Gross margin | 83.5% | 79.0% | 82.6% | 84.4% | 85.8% | 81.7% | 85.9% | 83.0% | 82.9% | 85.5% | 77.3% | 74.6% |
| Operating income | $287.7M | $184.5M | -$44.2M | $217.9M | $202.4M | $141.5M | $175.5M | $163.2M | $117.2M | $95.5M | $101.0M | $88.3M |
| Net income | $229.9M | $150.0M | -$141.6M | $175.2M | $165.2M | $118.1M | $137.0M | $137.0M | $93.2M | $76.8M | $85.4M | $81.8M |
| Net margin | 47.8% | 39.8% | −31.3% | 49.5% | 50.7% | 44.6% | 46.0% | 47.2% | 40.3% | 39.2% | 37.1% | 37.9% |
| Diluted EPS | $1.90 | $1.22 | $-1.16 | $1.43 | $1.33 | $0.93 | $1.06 | $1.05 | $0.72 | $0.60 | $0.65 | $0.61 |
| EBITDA | $321.6M | $218.3M | $267.4M | $238.3M | $222.9M | $162.0M | $195.9M | $181.9M | $139.2M | $115.7M | $101.0M | $111.4M |
| Operating cash flow | $240.9M | $180.1M | $219.0M | $178.6M | $99.7M | $154.2M | $178.5M | $115.4M | $55.8M | $129.4M | $102.4M | $132.4M |
| Free cash flow | $236.7M | $176.3M | $217.6M | $175.6M | $98.1M | $153.3M | $175.4M | $113.9M | $53.2M | $125.9M | $99.8M | $129.5M |
| Diluted shares | 121.2M | 122.9M | 122.5M | 122.3M | 124.2M | 126.6M | 129.5M | 130.1M | 129.2M | 128.9M | 131.3M | 134.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $163.1M | $309.7M | $133.8M | $419.7M | $61.9M | $176.3M |
| Short-term investments | $67.9M | $8.9M | $9.0M | $282.3M | $486.3M | $571.6M |
| Total debt | $2.15B | $2.14B | $2.14B | $1.51B | $1.51B | $1.51B |
| Total assets | $2.58B | $2.67B | $2.53B | $2.22B | $2.05B | $2.20B |
| Total liabilities | $2.43B | $2.45B | $2.48B | $1.72B | $1.72B | $1.71B |
| Shareholders' equity | $143.5M | $219.6M | $48.8M | $503.9M | $332.7M | $482.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology